Stockscreener 앱 받기
603.58
0.34%
-2.03
시간 외 거래:
603.71
0.13
+0.02%
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan
Schonfeld Strategic Advisors LLC Buys 18,496 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Aspire Growth Partners LLC Makes New $421,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Retinal Vein Occlusion Market Size, Trends & Growth Forecast - openPR.com
Mercer Global Advisors Inc. ADV Has $16.66 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Earnings Miss - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Quarterly Earnings Results, Misses Estimates By $0.61 EPS - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by TD Waterhouse Canada Inc. - MarketBeat
Public Employees Retirement Association of Colorado Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Voleon Capital Management LP Acquires Shares of 671 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by The Manufacturers Life Insurance Company - MarketBeat
California State Teachers Retirement System Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Northern Trust Corp Has $751.39 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria - MSN
Cantor Fitzgerald Issues Positive Outlook for REGN Earnings - MarketBeat
Westbourne Investments Inc. Purchases Shares of 500 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to “Hold” at StockNews.com - Defense World
UBS Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $633.00 - Defense World
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Nebula Research & Development LLC - MarketBeat
Regeneron (REGN) Declares Quarterly Dividend of $0.88/Share - GuruFocus
Retinal Vein Occlusion Market Projected To Witness Massive - openPR.com
AQR Capital Management LLC Sells 18,449 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition - insights.citeline.com
FY2025 EPS Estimates for REGN Raised by Cantor Fitzgerald - Defense World
Regeneron announces significant expansion of US manufacturing capacity - The Manufacturer
Aquatic Capital Management LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences - simplywall.st
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’ - MSN
Regeneron Pharmaceuticals (REGN) Price Target Lowered by Guggenh - GuruFocus
Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea - Seeking Alpha
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Regeneron to present new cancer treatment data at ASCO By Investing.com - Investing.com India
Regeneron to present new cancer treatment data at ASCO - Investing.com
Regeneron (REGN) to Unveil Key Oncology and Hematology Data at A - GuruFocus
Regeneron (REGN) to Showcase Dupixent Data at 2025 ATS Conferenc - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Revenue Concerns | - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Revenue Concerns | REGN Stock News - GuruFocus
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination - The Manila Times
Regeneron Pharmaceuticals to Present New Oncology and Hematology Data at 2025 ASCO Annual Meeting - Nasdaq
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases - Stock Titan
PDT Partners LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron (REGN) Faces Price Target Cut Amid Eylea Challenges | - GuruFocus
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Beacon Pointe Advisors LLC - MarketBeat
Stifel Financial Corp Has $27.13 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
MML Investors Services LLC Purchases 2,218 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years - Insider Monkey
Cantor Fitzgerald maintains Regeneron stock with $695 target By Investing.com - Investing.com South Africa
Robert W. Baird Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Another Regeneron CRL Prompts Regulatory Operations Questions - insights.citeline.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Shares Are Up Today: What's Going On? - Benzinga
Guggenheim Cuts Regeneron Pharmaceuticals' Price Target to $810 From $940 - marketscreener.com
Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar
1.07%
0.63%
자본화:
|
볼륨(24시간):